Comanche Biopharma
Develops an investigational siRNA medicine for preterm preeclampsia.
$75M Series B+ ·
Led by NEA · Source: startupintros.com
Latest round on record: Series B+, February 2025, amount undisclosed.
All 2 rounds ↓Signals
Comanche Biopharma | 245 days from X account to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | — | startupintros.com | |
| Series B+ | $75M | startupintros.com |
Timeline
- X account created
- Website created
Founders and team
MY
Mike Young Founder- SJScott Johnson Chief Executive Officer & Co-Foundersource: comanchebiopharma.com
TS
Thomas Scott Johnson FounderAA
Allison August Chief Medical OfficerRC
Richard Colvin Global Head of Research and Development
Investors
Similar Health and bio companies
VVumedi$140M Series B+ · Nov 2026
NNeurosterix$105M Series B+ · Nov 2026
OOSMUNDA$14.99M Series B+ · Nov 2026
BBoston Medical Sciences$34.69M Series B+ · Nov 2026
AAraceli Biosciences$4.5M Seed · Nov 2026
PPhrontline Biopharma$40M Series A · Nov 2026
Other companies backed by NEA
DDatabento$100M Series B+ · Nov 2026
BBasalt Health$20M Series A · Oct 2026
PPathos$237M Series B+ · Oct 2026
TTamr$21M Series B+ · Oct 2026
SSpiko Paris, France$90M Series B+ · Oct 2026
AAutomating software development$200M Series B+ · Sep 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/comanche-biopharma (get a free API key).